Subclinical hyperthyroidism is a risk factor for poor functional outcome after ischemic stroke
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Outcome measures were obtained at 3 months after stroke (median time: 90 days, interquartile range [IQR] 81-99 days), conducted by a structured interview via telephone or face to face depending on the patient's feasibility to return to the study center. The interview was performed with the patient or, if not possible, with a close relative. 160 patients completed the 3 months follow-up. Five patients died within 3 months and 5 were lost to follow-up (figure e-1). Statistical analyses were performed on the 165 patients with known functional outcome after 3 months. The representativeness of the 165 analyzed and 303 not analyzed patients with acute ischemic stroke is shown in table e-1.
Standard protocol approvals, registrations, and patient consent. The study was conducted according to the Declaration of Helsinki and approved by the local ethics committee. Written informed consent was obtained by patient or legal guardian prior to study participation.
Data collection.
Information on demographic variables, living situation, functional pre-stroke outcome, lifestyle habits, health history as well as medication before stroke was provided by the patient or the closest relative at baseline examination. Stroke severity was assessed using the National Institutes of Health Stroke Survey (NIHSS) by a certified study clinician. Stroke etiology was determined according to the criteria of the TOAST and ASCO classification. 1 Patients received a continuous 72h-ECG recording at baseline and a 12-channel ECG at the follow-up. Furthermore all patients received complete two-dimensional (2D) and Doppler echocardiography, however left atrial diameter, ejection fraction and premature atrial contractions were not quantitatively assessed. All examinations were performed and interpreted by an independent observer who was unaware of the clinical data.
Exposure measurement. Blood samples were drawn in the morning between 6 and 9 am to minimize variations caused by circadian rhythm. They were taken within 3 days after symptom onset and adjusted for time differences in multivariable analyses. Serum thyroidstimulating hormone (TSH), free thyroxin (fT4) and free tri-iodothyronine (fT3) concentrations were quantified using a chemiluminescence-based immunoassay implemented on a fully automated immunoanalyzer system (ADVIA Centaur TSH, Siemens Healthcare Diagnostics, Tarrytown NY, USA). 2 In the recent literature different reference-limits have been proposed for hypothyroidism:
Akhoundi et al. 3 defined subclinical hypothyroidism as serum TSH level in the range of 2.5-10mIU/L, Baek et al. 4 defined subclinical hypothyroidism as TSH >5μU/mL. In the current study we adopted the lower cut point of 2.5 to be comparable with the more recent work of Akhoundi et al. 3 For hyperthyroidism we adopted the cut point used by Cappola et al. 5 , who determined the relationship between baseline thyroid status and incident atrial fibrillation.
Thus, euthyroid state was defined by a serum TSH-level between 0.44 and 2.5 μU/ml, subclinical hyperthyroidism was defined by a serum TSH-level between 0.11 and 0.44 μU/ml plus normal fT4 and fT3 and subclinical hypothyroidism was defined by a serum TSHlevel between ≥2.5 and <20 μU/ml plus normal fT4 and fT3. 3, 5 Reference values for fT4 were 0.9-1.8 ng/dl and for fT3 2.3-4.2 pg/ml. All measurements were performed by laboratory staff unaware of the patients' clinical characteristics.
Outcome measurement. The modified Rankin Scale (mRS) was used as the primary functional outcome measure after 3 months follow-up as recommended in the literature. 6 The Barthel Index (BI) was used as a supporting scale to assess consistency in direction of effect. 6 Both outcome measurements were determined by trained raters who were unaware of the laboratory results.
Statistical analysis. Data are given as means (SD) for normally distributed interval variables, as medians (IQR) for skewed data or scores, and as frequencies (percentage) for categorical variables.
Associations between TSH and functional outcomes 3 months after stroke were determined using ordinal logistic regression with euthyroid state as reference because an ordinal analysis is statistically more powerful and avoids the difficulty of choosing one cut point. 6 LDL cholesterol, medication before stroke for dyslipidemia and mRS at baseline was not included in the multivariable models to avoid multicollinearity. All models were adjusted for the time between symptom onset and blood sampling. Continuous variables were categorized into quartiles to account for nonlinear relations with the outcome. Odds ratios (OR) were reported with 95% confidence intervals (CI). All analyses were two-sided, conducted at a 0.05 level of significance and carried out using SAS version 9.3 (SAS Institute Inc., Cary, NC). 
